Members only

 


The innovative hybrid Cobalt-Chromium Abluminal Biodegradable Polymer DES

BioMatrix™ Alpha presents the best in class stent platform design with unique pro-healing coating from the pioneer in abluminal biodegradable technology3.

It combines the proven safety of a DES with an abluminal biodegradable polymer, the proven efficacy of BA9™ and an innovative
cobalt-chromium stent platform design.
 
 

Abluminal coating absorbed after 6 to 9 months4
No drug carrier or drug inside the stent

  • Early BMS-like endothelial coverage2
  • More targeted drug release
  • Reduced systemic exposure

 

 

BA9™ Designed Specifically for Coronary Stent Application

 
 
 
  • Unique drug and proprietary of Biosensors International Group, Ltd.
  • Designed for properties that would support healing and re-endothelialization
  • Chemical characteristics allow:
       - delivered with synchronous absorption of proprietary PLA polymer
       - with no loss to the systemic system.

 

 


Alpha by Design best in class performance vs other stents2
 

11881-000-EN - Rev.04 - 12244-000-EN, 11582-000-EN, 10833-000-EN, 11447-000-EN - Rev.01 + 10801-000-EN - Rev.05
BioMatrix™ Alpha
Alpha by Design Animation
BioMatrix™ Alpha
BMX Alpha Registry 2Y FU Results

*.  Including iterations of the Nobori stent
1.  Clinical Outcomes with Cobalt Chromium Biolimus DES compared with Stainless Steel Biolimus DES in All-Comers Patients after 2 years. Presentation I. Menown TCT CONNECT 2020
2.  Data on file at Biosensors International Group, Ltd
3.  Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. Serruys P. et al JACC Cardiovasc Interv. 2013 Aug;6(8):777-89  First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry. Menown I et al. Int J Cardiol Heart Vasc. 2020 Jan 27;26:100472
4.  In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months. Data on file at Biosensors International
5. Sirolimus analog lipophilicity dictates release kinetics and tissue retention after implantation of polymer free drug eluting stents. R. Tzafriri, Poster Presentation EuroPCR 2017
6. Percentage change in stent length after applying 5N compression force longitudinally
7. Recoil measured as percentage change in diameter at RBP
 
BIOMATRIX™ FAMILY CLINICAL PROGRAM

CAUTION: Please note that the following pages are exclusively reserved for Health Care Professionals in countries with applicable health authority product registrations. To the extent this site contains information intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions. Please contact your Biosensors International representative for availability or the products and registration status.

The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix NeoFlex™, BioMatrix™ Alpha, BioFreedom™, BioFreedom™ Ultra, BMX-J® and RISE™ NC, are not available for sale in the United States and certain other countries. ALLEGRA™ is a product of NVT GmbH. Blue Sail Medical Co., Ltd is the ultimate parent company of NVT GmbH and Biosensors International Group, Ltd. and its subsidiaries are collaborating for the commercialization of the ALLEGRA™ device.

BioMatrix NeoFlex, BioMatrix Alpha, BioFreedom, BioFreedom Ultra, BMX-J, Juno, S-Stent and Rise NC are trademarks or registered trademarks of Biosensors International Group, Ltd. ALLEGRA is a trademark or registered trademark of NVT AG. All other cited trademarks are the property of their respective owners.